Hormonreceptor positive, Her-2 negative locally advanced or metastatic breast cancer patients could benefit from the therapy with CDK4/6 inhibitors (Palbociclib, Ribociclib, Abemaciclib). This oral medication combined with antihormonal therapy has been shown to achieve high response rates with a good quality of life.
If progression occurs, the tumor tissue of these patients should be tested for a PIK3Ca-mutation. This mutation can be found in 40% of hormone-dependent breast cancer patients and these patients would benefit of a PI3K inhibitor therapy (Alpelisib), which is also an oral medication and comes along with a good quality of life.
Patients with locally advanced or metastatic triple negative breast cancer could benefit from a kind of immunotherapy which is combined with chemotherapy: if their tumors would express PD-L1, they could be treated with PD-L1 inhibitors (Atezolizumab).